Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human phase 1 study of ATG-101 in patients with advanced solid tumors and Non-Hodgkin's-lymphoma

Next Previous
X
Search
Trial Profile

A first in human phase 1 study of ATG-101 in patients with advanced solid tumors and Non-Hodgkin's-lymphoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATG 101 (Primary)
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 31 Oct 2021 According to an Antengene Corporation media release, the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ATG-101 as a potential treatment for metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL).
    • 19 May 2021 New trial record
    • 17 May 2021 According to an Antengene Corporation media release, a clinical trial application is planned to be submitted for this first in human (FIH) study of ATG-101 in USA after its submission of CTA in Australia in mid 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top